Codagenix, a Stony Brook biotech company, has closed on $322,000 in public and private funding, including the latest investment from Accelerate Long Island and the Long Island Emerging Technologies Fund. Read more about the company and the funding from Accelerate Long Island and Newsday.com.
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3428
[post_author] => 3
[post_date] => 2020-01-22 14:42:19
[post_date_gmt] => 2020-01-22 14:42:19
[post_content] => IO360˚ convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. The 6th annual Immuno-Oncology 360° Summit is the premier meeting across all stakeholders in IO, addressing the rapid advancements of clinical, scientific and business developments of IO in one setting to help develop therapeutics for a wider range of cancers at an accelerated rate.
The 3 day summit features more than 80 time sensitive IO topics, over 500 senior level thought leaders and includes over 10 hours of networking. Use the code CFB20 for a 20% discount. For more information please visit:
www.io360summit.com
[post_title] => Immuno-Oncology 360˚ - February 26-28, 2020
[post_excerpt] => IO360˚addresses the rapid advancements of clinical, scientific and business developments of IO. Discount registration available for CFB constituents.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => immuno-oncology-360%cb%9a-february-26-28-2020
[to_ping] =>
[pinged] =>
[post_modified] => 2020-01-22 14:42:19
[post_modified_gmt] => 2020-01-22 14:42:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3428
[menu_order] => 77
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3131
[post_author] => 4
[post_date] => 2019-01-24 15:24:44
[post_date_gmt] => 2019-01-24 15:24:44
[post_content] => BARDA’s DRIVe is pleased to announce the expansion of its market research effort to identify potential partners and capture feedback to support its newest novel public-private partnership, DRIVe Ventures. DRIVe Ventures will work with corporate venture capital partners to invest in promising products, driving them to the marketplace to transform and enhance national health security.
BARDA DRIVe seeks feedback on a potential new novel public-private partnership that leverages venture capital practices and methods to disrupt the way BARDA invests in health security innovation. Learn more.
[post_title] => Request for Information: BARDA DRIVe Ventures
[post_excerpt] => BARDA DRIVe wants to hear from the venture capital community – looking for feedback to support its newest novel public-private partnership, DRIVe Ventures.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => request-for-information-barda-drive-ventures
[to_ping] =>
[pinged] =>
[post_modified] => 2019-04-09 14:41:07
[post_modified_gmt] => 2019-04-09 14:41:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3131
[menu_order] => 104
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2486
[post_author] => 4
[post_date] => 2016-11-22 16:36:20
[post_date_gmt] => 2016-11-22 16:36:20
[post_content] => The application period for the SUNY Technology Accelerator Fund Class of 2017 is now open.
The SUNY Technology Accelerator Fund (TAF) provides investments to support the advancement of SUNY innovations from the lab to the marketplace. TAF investments are made on a highly competitive basis in projects that target critical research and development milestones, such as feasibility studies, prototyping and testing, which demonstrate that an idea or innovation has commercial potential.
Faculty, staff, and students from all disciplines and campuses are encouraged to submit proposals for the SUNY Technology Accelerator Fund Class of 2017 funding. The deadline for submitting proposals is March 20, 2017. See TAF Class of 2017 Application and Administrative Guidelines.
Please be advised that all proposals require the review and participation of your campus administration prior to submission. To be certain that you adhere to any local proposal submission deadlines, you are urged to immediately contact your technology transfer office and/or office of sponsored programs if you are interested in applying for TAF Class of 2017 funding.
Jointly funded by the State University of New York and the Research Foundation, the Technology Accelerator Fund has invested over $2 million since its launch in April 2011, and brought to life 36 of SUNY’s most promising technologies by catalyzing the investment of an additional $4.1 million from external partners, including federal agencies, industry licensees and angel investors. To learn about the technologies in which TAF has invested and the people who made it happen, see Technology Accelerator Funded Projects.
Questions? Please send any questions to TAF@rfsuny.org. All questions and answers will be posted to www.rfsuny.org/taf.
[post_title] => Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals
[post_excerpt] => The SUNY Technology Accelerator Fund (TAF) provides investments to support the advancement of SUNY innovations from the lab to the marketplace. The application period for the SUNY TAF Class of 2017 is now open.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => funding-opportunity-suny-technology-accelerator-fund-accepting-proposals
[to_ping] =>
[pinged] =>
[post_modified] => 2016-11-30 15:19:35
[post_modified_gmt] => 2016-11-30 15:19:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2486
[menu_order] => 159
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 288
[max_num_pages] => 96
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)